Screening for HIV

Systematic review to update the 2005 U.S. Preventive Services Task Force recommendation

Roger Chou, Shelley Selph, Tracy Dana, Christina Bougatsos, Bernadette Zakher, Ian Blazina, Philip (Todd) Korthuis

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that HIV screening is accurate and that antiretroviral therapy (ART) for immunologically advanced disease is associated with substantial clinical benefits, but insufficient evidence to determine the effects on transmission or in less immunologically advanced disease. Purpose: To update the 2005 USPSTF review on benefits and harms of HIV screening in adolescents and adults, focusing on research gaps identified in the prior review. Data Sources: MEDLINE (2004 to June 2012) and the Cochrane Library (through the second quarter of 2012). Study Selection: Randomized trials and observational studies that compared HIV screening strategies and reported clinical outcomes, evaluated the effects of starting ART at different CD4 cell count thresholds and long-term harms, or reported the effects of interventions on transmission risk. Data Extraction: 2 authors abstracted and checked study details and quality using predefined criteria. Data Synthesis: No study directly evaluated the effects on clinical outcomes of screening versus no screening for HIV infection. A randomized trial and a subgroup analysis from a randomized trial found that ART initiation at CD4 counts less than 0.250 × 109 cells/L was associated with a higher risk for death or AIDS-defining events than initiation at CD4 counts greater than 0.350 × 109 cells/L (hazard ratios, 1.7 [95% CI, 1.1 to 2.5] and 5.3 [CI, 1.3 to 9.6]). Large, fair-quality cohort studies also consistently found that ART initiation at CD4 counts of 0.350 to 0.500 × 109 cells/L was associated with lower risk for death or AIDS-defining events than delayed initiation. New evidence from good-quality cohorts with longer-term follow-up confirms a previously observed small increased risk for cardiovascular events associated with certain antiretrovirals. Strong evidence from 1 good-quality randomized trial and 7 observational studies found that ART was associated with a 10- to 20-fold reduction in risk for sexual transmission of HIV. Limitations: Only English-language articles were included. Observational studies were included. Studies done in resource-poor or high-prevalence settings were included but might have limited applicability to general screening in the United States. Conclusion: Previous studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk for AIDS-defining events and death in persons with less advanced immunodeficiency and reduces sexual transmission of HIV. Primary Funding Source: Agency for Healthcare Research and Quality.

Original languageEnglish (US)
Pages (from-to)706-718
Number of pages13
JournalAnnals of Internal Medicine
Volume157
Issue number10
StatePublished - Nov 20 2012

Fingerprint

Advisory Committees
HIV
CD4 Lymphocyte Count
Observational Studies
Acquired Immunodeficiency Syndrome
Therapeutics
Information Storage and Retrieval
Health Services Research
Risk Reduction Behavior
MEDLINE
Libraries
HIV Infections
Cohort Studies
Language
Research

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Screening for HIV : Systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. / Chou, Roger; Selph, Shelley; Dana, Tracy; Bougatsos, Christina; Zakher, Bernadette; Blazina, Ian; Korthuis, Philip (Todd).

In: Annals of Internal Medicine, Vol. 157, No. 10, 20.11.2012, p. 706-718.

Research output: Contribution to journalArticle

@article{e0abba4513fc483e8c946ae2903b2d0a,
title = "Screening for HIV: Systematic review to update the 2005 U.S. Preventive Services Task Force recommendation",
abstract = "Background: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that HIV screening is accurate and that antiretroviral therapy (ART) for immunologically advanced disease is associated with substantial clinical benefits, but insufficient evidence to determine the effects on transmission or in less immunologically advanced disease. Purpose: To update the 2005 USPSTF review on benefits and harms of HIV screening in adolescents and adults, focusing on research gaps identified in the prior review. Data Sources: MEDLINE (2004 to June 2012) and the Cochrane Library (through the second quarter of 2012). Study Selection: Randomized trials and observational studies that compared HIV screening strategies and reported clinical outcomes, evaluated the effects of starting ART at different CD4 cell count thresholds and long-term harms, or reported the effects of interventions on transmission risk. Data Extraction: 2 authors abstracted and checked study details and quality using predefined criteria. Data Synthesis: No study directly evaluated the effects on clinical outcomes of screening versus no screening for HIV infection. A randomized trial and a subgroup analysis from a randomized trial found that ART initiation at CD4 counts less than 0.250 × 109 cells/L was associated with a higher risk for death or AIDS-defining events than initiation at CD4 counts greater than 0.350 × 109 cells/L (hazard ratios, 1.7 [95{\%} CI, 1.1 to 2.5] and 5.3 [CI, 1.3 to 9.6]). Large, fair-quality cohort studies also consistently found that ART initiation at CD4 counts of 0.350 to 0.500 × 109 cells/L was associated with lower risk for death or AIDS-defining events than delayed initiation. New evidence from good-quality cohorts with longer-term follow-up confirms a previously observed small increased risk for cardiovascular events associated with certain antiretrovirals. Strong evidence from 1 good-quality randomized trial and 7 observational studies found that ART was associated with a 10- to 20-fold reduction in risk for sexual transmission of HIV. Limitations: Only English-language articles were included. Observational studies were included. Studies done in resource-poor or high-prevalence settings were included but might have limited applicability to general screening in the United States. Conclusion: Previous studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk for AIDS-defining events and death in persons with less advanced immunodeficiency and reduces sexual transmission of HIV. Primary Funding Source: Agency for Healthcare Research and Quality.",
author = "Roger Chou and Shelley Selph and Tracy Dana and Christina Bougatsos and Bernadette Zakher and Ian Blazina and Korthuis, {Philip (Todd)}",
year = "2012",
month = "11",
day = "20",
language = "English (US)",
volume = "157",
pages = "706--718",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Screening for HIV

T2 - Systematic review to update the 2005 U.S. Preventive Services Task Force recommendation

AU - Chou, Roger

AU - Selph, Shelley

AU - Dana, Tracy

AU - Bougatsos, Christina

AU - Zakher, Bernadette

AU - Blazina, Ian

AU - Korthuis, Philip (Todd)

PY - 2012/11/20

Y1 - 2012/11/20

N2 - Background: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that HIV screening is accurate and that antiretroviral therapy (ART) for immunologically advanced disease is associated with substantial clinical benefits, but insufficient evidence to determine the effects on transmission or in less immunologically advanced disease. Purpose: To update the 2005 USPSTF review on benefits and harms of HIV screening in adolescents and adults, focusing on research gaps identified in the prior review. Data Sources: MEDLINE (2004 to June 2012) and the Cochrane Library (through the second quarter of 2012). Study Selection: Randomized trials and observational studies that compared HIV screening strategies and reported clinical outcomes, evaluated the effects of starting ART at different CD4 cell count thresholds and long-term harms, or reported the effects of interventions on transmission risk. Data Extraction: 2 authors abstracted and checked study details and quality using predefined criteria. Data Synthesis: No study directly evaluated the effects on clinical outcomes of screening versus no screening for HIV infection. A randomized trial and a subgroup analysis from a randomized trial found that ART initiation at CD4 counts less than 0.250 × 109 cells/L was associated with a higher risk for death or AIDS-defining events than initiation at CD4 counts greater than 0.350 × 109 cells/L (hazard ratios, 1.7 [95% CI, 1.1 to 2.5] and 5.3 [CI, 1.3 to 9.6]). Large, fair-quality cohort studies also consistently found that ART initiation at CD4 counts of 0.350 to 0.500 × 109 cells/L was associated with lower risk for death or AIDS-defining events than delayed initiation. New evidence from good-quality cohorts with longer-term follow-up confirms a previously observed small increased risk for cardiovascular events associated with certain antiretrovirals. Strong evidence from 1 good-quality randomized trial and 7 observational studies found that ART was associated with a 10- to 20-fold reduction in risk for sexual transmission of HIV. Limitations: Only English-language articles were included. Observational studies were included. Studies done in resource-poor or high-prevalence settings were included but might have limited applicability to general screening in the United States. Conclusion: Previous studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk for AIDS-defining events and death in persons with less advanced immunodeficiency and reduces sexual transmission of HIV. Primary Funding Source: Agency for Healthcare Research and Quality.

AB - Background: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that HIV screening is accurate and that antiretroviral therapy (ART) for immunologically advanced disease is associated with substantial clinical benefits, but insufficient evidence to determine the effects on transmission or in less immunologically advanced disease. Purpose: To update the 2005 USPSTF review on benefits and harms of HIV screening in adolescents and adults, focusing on research gaps identified in the prior review. Data Sources: MEDLINE (2004 to June 2012) and the Cochrane Library (through the second quarter of 2012). Study Selection: Randomized trials and observational studies that compared HIV screening strategies and reported clinical outcomes, evaluated the effects of starting ART at different CD4 cell count thresholds and long-term harms, or reported the effects of interventions on transmission risk. Data Extraction: 2 authors abstracted and checked study details and quality using predefined criteria. Data Synthesis: No study directly evaluated the effects on clinical outcomes of screening versus no screening for HIV infection. A randomized trial and a subgroup analysis from a randomized trial found that ART initiation at CD4 counts less than 0.250 × 109 cells/L was associated with a higher risk for death or AIDS-defining events than initiation at CD4 counts greater than 0.350 × 109 cells/L (hazard ratios, 1.7 [95% CI, 1.1 to 2.5] and 5.3 [CI, 1.3 to 9.6]). Large, fair-quality cohort studies also consistently found that ART initiation at CD4 counts of 0.350 to 0.500 × 109 cells/L was associated with lower risk for death or AIDS-defining events than delayed initiation. New evidence from good-quality cohorts with longer-term follow-up confirms a previously observed small increased risk for cardiovascular events associated with certain antiretrovirals. Strong evidence from 1 good-quality randomized trial and 7 observational studies found that ART was associated with a 10- to 20-fold reduction in risk for sexual transmission of HIV. Limitations: Only English-language articles were included. Observational studies were included. Studies done in resource-poor or high-prevalence settings were included but might have limited applicability to general screening in the United States. Conclusion: Previous studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk for AIDS-defining events and death in persons with less advanced immunodeficiency and reduces sexual transmission of HIV. Primary Funding Source: Agency for Healthcare Research and Quality.

UR - http://www.scopus.com/inward/record.url?scp=84869757726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869757726&partnerID=8YFLogxK

M3 - Article

VL - 157

SP - 706

EP - 718

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -